Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Arcellx, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Investor Contact:"
08/07/2023 4 Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 3,000 shares @ $35.3778, valued at $106.1k
Exercised 3,000 options to buy @ $15, valued at $45k
08/04/2023 144 Form 144 - Report of proposed sale of securities:
07/21/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/05/2023 4 Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 3,000 shares @ $31.7487, valued at $95.2k
Exercised 3,000 options to buy @ $15, valued at $45k
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/16/2023 4 Carroll Jill (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Granted 11,459 options to buy @ $37.94, valued at $434.8k
06/16/2023 4 Behbahani Ali (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Granted 11,459 options to buy @ $37.94, valued at $434.8k
06/16/2023 4 Yoon Derek (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Granted 11,459 options to buy @ $37.94, valued at $434.8k
06/16/2023 4 Ware Olivia C (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Granted 11,459 options to buy @ $37.94, valued at $434.8k
06/16/2023 4 Patel Kavita (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Granted 11,459 options to buy @ $37.94, valued at $434.8k
06/16/2023 4 Lubner David Charles (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Granted 11,459 options to buy @ $37.94, valued at $434.8k
06/05/2023 4 Behbahani Ali (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Acquired 113 shares @ $0
Acquired 28 shares @ $0
06/02/2023 4 Elghandour Rami (See Remarks) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 2,600 shares @ $44.2688, valued at $115.1k
06/02/2023 4 Carroll Jill (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 315,164 shares @ $41.5, valued at $13.1M
Sold 25,556 shares @ $44.3464, valued at $1.1M
06/02/2023 SC 13D/A SR ONE CAPITAL MANAGEMENT, LLC reports a 8.2% stake in Arcellx, Inc.
05/31/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 4 Gilson Michelle (CFO) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 8,554 shares @ $42.47, valued at $363.3k
Sold 150 shares @ $41.64, valued at $6.2k
Sold 6,000 shares @ $42.7694, valued at $256.6k
Exercised 22,428 restricted stock units @ $0
05/25/2023 144 Form 144 - Report of proposed sale of securities:
05/19/2023 SC 13D/A SR ONE CAPITAL MANAGEMENT, LLC reports a 9.4% stake in Arcellx, Inc.
05/15/2023 4 Carroll Jill (Director) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 631,932 shares @ $45, valued at $28.4M
Sold 6,485 shares @ $46.15, valued at $299.3k
05/15/2023 4 SR ONE CAPITAL MANAGEMENT, LLC (10% Owner) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 631,932 shares @ $45, valued at $28.4M
Sold 370,612 shares @ $45, valued at $16.7M
Sold 6,485 shares @ $46.15, valued at $299.3k
Sold 3,804 shares @ $46.15, valued at $175.6k
05/11/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 4 Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 500 shares @ $45, valued at $22.5k
Sold 2,197 shares @ $45.1824, valued at $99.3k
05/09/2023 10-Q/A Quarterly Report for the period ended March 31, 2023 [amend]
05/08/2023 4 Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 1,200 shares @ $45.0017, valued at $54k
05/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
05/08/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Arcellx Provides First Quarter Financial Results REDWOOD CITY, Calif., May 8, 2023 /PRNewswire/ -- Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023. “Delivering our novel CAR-T therapy to multiple myeloma patients is at the heart of our mission,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “With the closing of our Kite partnership in the first quarter, we believe we are well capitalized to fund our operations through the first half of 2025. We remain laser-focused on key drivers of our business which include completing enrollment of iMMagine-1, i..."
05/05/2023 4 Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.
Txns: Sold 400 shares @ $42.715, valued at $17.1k
Sold 2,600 shares @ $43.5551, valued at $113.2k
Exercised 3,000 options to buy @ $15, valued at $45k
05/03/2023 144 Form 144 - Report of proposed sale of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy